

Voluntary Disclosure of Payments to Healthcare Professionals and Healthcare Organizations For the period of January to December 2023

In June 2017, AbbVie, along with nine other Canadian pharmaceutical companies – all members of Innovative Medicines Canada – began publishing aggregated sums of their payments to Canadian HCPs and Healthcare Organizations (HCOs).

Bringing greater transparency to our valuable and well-regulated relationships will increase understanding of existing collaborations across our sector and will contribute to enhancing trust and value for both patients and the healthcare system.

The Voluntary Framework on Disclosure was developed by [Innovative Medicines Canada](#). As a partner in Canada's health care system, AbbVie Corporation regularly collaborates with healthcare professionals (HCPs) and healthcare organizations (HCOs) to foster scientific exchange, for the ultimate benefit of patients. These collaborations are bound by local and international laws and regulated by Innovative Medicine Canada's [Code of Ethical Practices](#). AbbVie Corporation's decision to publish our payments to HCPs and HCOs is voluntary and part of our overall commitment to greater transparency and high ethical standards in our business practices.

To continue to advance and evolve this framework, AbbVie remains committed to collaborating with health system stakeholders to further understand their needs.

All payment information has been captured in aggregate form (one sum total) and presented below in three categories.

Please note that in July 2022, Allergan Inc was amalgamated with AbbVie Corporation. The amounts listed below include payments to Canadian HCPs and Healthcare Organizations (HCOs) done by Allergan Pharma division from January 1 to December 31, 2023, and exclude payments done by the Allergan Aesthetics division.



Fee for HCP
Services
\$11,798,339*



Funding to HCOs
\$1,304,784*



Sponsorship of
HCP Travel
\$851,034*

* Payments exclude applicable taxes.

The values provided may include certain related incidental expenses and their applicable taxes.

Payments made for services rendered by a Canadian HCP for an international affiliate of the company are excluded.

Transfer of Value (ToV) is captured according to the payment date and not necessarily the date on which the activity occurred. Therefore, some activities in 2022 are reported as ToVs in 2023, and some activities that occurred in 2023 will be reported in the 2024 report.

The Company has used its reasonable best efforts to capture the most comprehensive data possible according to its knowledge and interpretation of the Voluntary Framework of Payments to HCPs/HCOs.

While the Company makes every effort to present accurate and reliable information, the Company makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. The Company shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by the Company or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and the Company is not responsible for the contents of or the availability of access to such websites.